Keep pulling the thread on Najat Khan.
Recursion synthesizes an average of 330 compounds to identify a final drug candidate, compared to an industry average of 5,000.
Recursion's drug design process takes an average of 17 months, compared to an industry average of 42 months.
Recursion's platform identified that an allosteric MEK1/2 inhibitor can reverse the cellular phenotype of APC gene loss-of-function, a novel biological insight.
In clinical trials, Recursion's drug for familial adenomatous polyposis (FAP) demonstrated a 43% median reduction in polyp burden.
Recursion's FAP drug achieved its median polyp reduction after three months of treatment, whereas other experimental drugs have taken 12 months to achieve approximately half that effect.
Recursion plans to begin conversations with the FDA this year to design a Phase 3 registrational study for its familial adenomatous polyposis (FAP) drug.
Recursion has generated a dataset of one trillion iPSC-derived neuronal cells in which every gene in the human genome has been knocked out.
Recursion positions itself as the first end-to-end, AI-native platform company for drug discovery and development.
Recursion's integration with Exscientia expanded its capabilities from novel biology discovery to AI-driven small molecule design.
Recursion's strategy is to be an end-to-end platform covering biology, chemistry, and clinical development, differentiating it from competitors who focus on point solutions.
The non-profit organization Stand Up to Cancer has raised over $800 million for cancer research.
Patients with familial adenomatous polyposis (FAP) have a 100% risk of developing colorectal cancer if the condition is left untreated.